Global Cancer Monoclonal Antibodies Market &Clinical Trial Insight 2024

Publish Date:- Nov-2018       No Of Pages (1100)

Electronic Access - Single User License $3000 Buy Now
CD-ROM Mail Delivery $4200Buy Now
Hard Copy Mail Delivery $5100 Buy Now
Electronic Access - Multi-User License $5500 Buy Now


 " Global Cancer Monoclonal Antibodies  Market &Clinical Trial Insight 2024" Report Highlights:

 
  • Significance for Monoclonal Antibodies for Cancer Treatment
  • Global Cancer Monoclonal Antibodies Market Overview
  • Global Cancer Monoclonal Antibodies Pipeline by Phase & Indication
  • Global Cancer Monoclonal Antibodies Pipeline: 697 mAb
  • Marketed Cancer Monoclonal Antibodies: 60
  • Global Cancer Monoclonal Antibodies Market Opportunity: US$ 140 Billion

 

The recent years have witnessed the emergence of monoclonal antibodies, which has the potential to offer less toxic and more efficient therapeutic alternatives for patients. Over the past decades, the researchers have increased their learning about the human body’s immune system, which has led to the achievement of significant number of regulatory milestones during this period. The use of mAbs for treating cancer has increased significantly. The rising market availability of these agents has enabled the pharmaceutical companies to develop novel combination approaches which have the capability to provide even greater insight into the body’s immune system so as to develop more efficient mAbs.

Though the monoclonal antibodies are already a significant part of the treatment for many cancers, the use of these antibodies in other aspects of cancer treatment is yet to be tapped. In this regard, research is currently being undertaken to understand deeply the process and reason for cancer cells being different from normal cells and the use of mAbs to exploit these differences. This has led to the development of many newer forms of mAbs, which are being attached to drugs or other substances thus making them more powerful.

The pharma companies are also looking for ways and means to make these drugs more safe and effective. As an illustration, since mAbs are proteins, there is a high chance that these antibodies could possibly make the body’s immune system react against them, which could result in many side effects, and also destruction of the mAbs. The newly developed forms of mAbs are a solution to this problem and are less likely to cause immune reactions.

Pharma companies are also working on the options for using only some specific parts of antibodies to develop improvised drugs. Another approach which is also currently being analyzed is to combine parts of two antibodies together (known as a bispecific antibody). In this process, one part could possibly attach to a cancer cell, while the other could attach to an immune cell, which would eventually bring both together. Thus, the future years are likely to witness an increased use of mAbs in different forms in treating cancer so as to provide better treatment options and thus improve the patient’s lives. The pharma companies have realized the potential of mAbs in this field and are focusing their efforts in developing these antibodies at the earliest to capture a significant market share.

It is expected that during the next decade, with the discovery and introduction of new tumor-specific proteins, newer MAb targets would be successfully identified for regulating tumor cell growth or inducing apoptosis. Additionally, the changes in MAb would also allow for more efficient radionuclide or cytotoxic MAb drug targeting or lead to more efficient activation of host effector mechanisms which tend to lead to better therapeutic antibodies. 


 " Global Cancer Monoclonal Antibodies  Market &Clinical Trial Insight 2024" Report Highlights:

 
  • Significance for Monoclonal Antibodies for Cancer Treatment
  • Global Cancer Monoclonal Antibodies Market Overview
  • Global Cancer Monoclonal Antibodies Pipeline by Phase & Indication
  • Global Cancer Monoclonal Antibodies Pipeline: 697 mAb
  • Marketed Cancer Monoclonal Antibodies: 60
  • Global Cancer Monoclonal Antibodies Market Opportunity: US$ 140 Billion

 

The recent years have witnessed the emergence of monoclonal antibodies, which has the potential to offer less toxic and more efficient therapeutic alternatives for patients. Over the past decades, the researchers have increased their learning about the human body’s immune system, which has led to the achievement of significant number of regulatory milestones during this period. The use of mAbs for treating cancer has increased significantly. The rising market availability of these agents has enabled the pharmaceutical companies to develop novel combination approaches which have the capability to provide even greater insight into the body’s immune system so as to develop more efficient mAbs.

Though the monoclonal antibodies are already a significant part of the treatment for many cancers, the use of these antibodies in other aspects of cancer treatment is yet to be tapped. In this regard, research is currently being undertaken to understand deeply the process and reason for cancer cells being different from normal cells and the use of mAbs to exploit these differences. This has led to the development of many newer forms of mAbs, which are being attached to drugs or other substances thus making them more powerful.

The pharma companies are also looking for ways and means to make these drugs more safe and effective. As an illustration, since mAbs are proteins, there is a high chance that these antibodies could possibly make the body’s immune system react against them, which could result in many side effects, and also destruction of the mAbs. The newly developed forms of mAbs are a solution to this problem and are less likely to cause immune reactions.

Pharma companies are also working on the options for using only some specific parts of antibodies to develop improvised drugs. Another approach which is also currently being analyzed is to combine parts of two antibodies together (known as a bispecific antibody). In this process, one part could possibly attach to a cancer cell, while the other could attach to an immune cell, which would eventually bring both together. Thus, the future years are likely to witness an increased use of mAbs in different forms in treating cancer so as to provide better treatment options and thus improve the patient’s lives. The pharma companies have realized the potential of mAbs in this field and are focusing their efforts in developing these antibodies at the earliest to capture a significant market share.

It is expected that during the next decade, with the discovery and introduction of new tumor-specific proteins, newer MAb targets would be successfully identified for regulating tumor cell growth or inducing apoptosis. Additionally, the changes in MAb would also allow for more efficient radionuclide or cytotoxic MAb drug targeting or lead to more efficient activation of host effector mechanisms which tend to lead to better therapeutic antibodies. 

1. Introduction to Monoclonal Antibodies

  1.1 History of Development

  1.2 Working of Monoclonal Antibodies

 

2. Monoclonal Antibodies Classification

  2.1 Naked Monoclonal Antibodies

  2.2 Conjugated Monoclonal Antibodies

    2.2.1 Radiolabeled Antibodies

    2.2.2 Chemolabeled Antibodies

    2.2.3 Immunotoxins

 

3. Monoclonal Antibodies Mechanisms

  3.1 Tumor Antigens as Targets of Antibodies

  3.2 Development of Antibodies for Clinical Purposes

  3.3 Complement Dependent Cytotoxicity (CDC)

  3.4 Signal Transduction Changes

 

4. Significance for Monoclonal Antibodies for Cancer Treatment

 

5. Global Cancer Monoclonal Antibodies Market Overview

  5.1 Current Market Scenario

  5.2 Clinical Pipeline Insight

 

6. Global Cancer Monoclonal Antibodies Market Future Outlook

 

7. Global - Bladder Cancer Monoclonal Antibodies Clinical Pipeline by Company & Phase

  7.1 Phase-I/II

  7.2 Phase-II

  7.3 Phase-III

 

8. Marketed Bladder Cancer Monoclonal Antibodies Clinical Insight

  8.1 Durvalumab (Imfinzi)

 

9. Global - Blood Cancer Monoclonal Antibodies Clinical Pipeline by Company & Phase

  9.1 Unknown

  9.2 Research

  9.3 Preclinical

  9.4 Clinical

  9.5 Phase-I

  9.6 Phase-I/II

  9.7 Phase-II

  9.8 Phase-III

  9.9 Preregistration

 

10. Marketed Blood Cancer Monoclonal Antibodies Clinical Insight

  10.1 Daratumumab (DARZALEX)

  10.2 Ofatumumab (Arzerra)

  10.3 Obinutuzumab (GAZYVA, Gazyva & Gazyvaro)

  10.4 Blinatumomab (Blincyto)

  10.5 Elotuzumab (Empliciti)

  10.6 Mogamulizumab (Poteligeo)

  10.7 Alemtuzumab (Campath, Lemtrada, MabCampath, MabKampat & Remniq)

  10.8 Brentuximab Vedotin (Adcetris)

  10.9 Inotuzumab Ozogamicin (BESPONSA & Besponsa)

  10.10 Rituximab Biosimilar (AcellBia, Acellbia & USMAL)

  10.11 Rituximab Biosimilar (Blitzima, Ritemvia, Truxima & Tuxella)

  10.12 Rituximab Biosimilar (Rixathon & Riximyo)

  10.13 Gemtuzumab Ozogamicin (Mylotarg)

  10.14 Ibritumomab Tiuxetan (Zevalin & Zevamab)

  10.15 Rituximab Biosimilar (REDDITUX, Reditux & Tidecron)

  10.16 Rituximab Biosimilar (Novex)

  10.17 Rituximab Biosimilar (CIMAbior & RituxCIM)

  10.18 Rituximab/Hyaluronidase (MabThera SC, RITUXAN SC & Rituxan Hycela)

  10.19 Rituximab Biosimilar (Zytux)

  10.20 Rituximab Biosimilar (RituxiRel, Toritz & Toritz RA)

  10.21 Rituximab Biosimilar (Maball)

  10.22 Rituximab Biosimilar (Kikuzubam)

  10.23 Rituximab Biosimilar (Mabtas)

 

11. Global - Breast Cancer Monoclonal Antibodies Clinical Pipeline by Company & Phase

  11.1 Unknown

  11.2 Research

  11.3 Preclinical

  11.4 Phase-I

  11.5 Phase-II

  11.6 Phase-III

  11.7 Preregistration

  11.8 Registered

 

12. Marketed Breast Cancer Monoclonal Antibodies Clinical Insight

  12.1 Trastuzumab Subcutaneous (Herceptin SC)

  12.2 Pertuzumab (Omnitarg & Perjeta)

  12.3 Trastuzumab Biosimilar (CANMAb, Hertraz, Ogivri & Zedora)

  12.4 Trastuzumab Emtansine (Kadcyla)

  12.5 Trastuzumab Biosimilar (Vivitra)

 

13. Global Bone Cancer Monoclonal Antibodies Clinical Pipeline by Company & Phase

  13.1 Phase-III

 

14. Marketed Bone Cancer Monoclonal Antibodies Clinical Insight

  14.1 Denosumab (PRALIA, Prolia, Ranmark & Xgeva)

 

15. Global - Brain Cancer Monoclonal Antibodies Clinical Pipeline by Company & Phase

  15.1 Preclinical

  15.2 Phase-I/II

  15.3 Phase-III

  15.4 Registered

 

16. Marketed Brain Cancer Monoclonal Antibodies Clinical Insight

  16.1 Dinutuximab (Unituxin)

 

17. Global - Cervical Cancer Monoclonal Antibodies Clinical Pipeline by Company & Phase

  17.1 Phase-I/II

 

18. Global - Colorectal Cancer Monoclonal Antibodies Clinical pipeline by Company & Phase

  18.1 Unknown

  18.2 Preclinical

  18.3 Phase-I

 

19. Global - Head and Neck Cancer Monoclonal Antibodies Clinical Pipeline by Company & Phase

  19.1 Preclinical

  19.2 Phase-I/II

  19.3 Phase-III

 

20. Global - Liver Cancer Monoclonal Antibodies Clinical Pipeline by Company & Phase        

  20.1 Phase-II

 

21. Global - Kidney Cancer Monoclonal Antibodies Clinical Pipeline by Company & Phase

  21.1 Preclinical

  21.2 Phase-II

  21.3 Phase-III

 

22. Global - Skin Cancer Monoclonal Antibodies Clinical Pipeline by Company & Phase

  22.1 Research

  22.2 Preclinical

  22.3 Phase-I

  22.4 Phase-I/II

  22.5 Phase-II/III

  22.6 Phase-III

  22.7 Preregistration

 

23. Marketed Skin Cancer Monoclonal Antibodies Clinical Insight

  23.1 Avelumab (BAVENCIO)

  23.2 Olaratumab (Lartruvo)

 

24. Global - Stomach Cancer Monoclonal Antibodies Clinical Pipeline by Company & Phase

  24.1 Preclinical

  24.2 Phase-I/II

  24.3 Phase-II

  24.4 Phase-III

  24.5 Preregistration

 

25. Marketed Stomach Cancer Monoclonal Antibodies Clinical

  25.1 Bevacizumab Biosimilar (Bevax)

  25.2 Cetuximab Biosimilar – CinnaGen

  25.3 Bevacizumab Biosimilar (Cizumab)

 

26. Global - Lung Cancer Monoclonal Antibodies Clinical Pipeline by Company & Phase

  26.1 Research

  26.2 Clinical

  26.3 Phase-I

  26.4 Phase-I/II

  26.5 Phase-II

  26.6 Phase-II/III

  26.7 Phase-III

  26.8 Preregistration

  26.9 Registered

 

27. Marketed Lung Cancer Monoclonal Antibodies Clinical Insight

  27.1 Necitumumab (Portrazza)

  27.2 Iodine I 131 Derlotuximab Biotin (Cotara)

  27.3 Bevacizumab Biosimilar (Bryxta)

  27.4 Racotumomab (Vaxira)

  27.5 Racotumomab (Vaxira)

  27.6 Tc 99m Nofetumomab Merpentan (VerLuma)

 

28. Global - Ovarian Cancer Monoclonal Antibodies Clinical Pipeline by Company & Phase

  28.1 Research

  28.2 Preclinical

  28.3 Phase-I

  28.4 Phase-I/II

  28.5 Phase-II

 

29. Global - Pancreatic Cancer Monoclonal Antibodies Clinical Pipeline by Company & Phase

  29.1 Preclinical

  29.2 Phase-I

  29.3 Phase-I/II

  29.4 Phase-II

 

30. Marketed Pancreatic Cancer Monoclonal Antibodies Clinical Insight

  30.1 Gemcitabine elaidate companion diagnostic - Ventana Medical Systems/Clovis Oncology

 

31. Global - Prostate Cancer Monoclonal Antibodies Clinical Pipeline by Company & Phase

  31.1 Preclinical

  31.2 Phase-II

 

32. Global - Multiple Cancer Monoclonal Antibodies Clinical Pipeline by Company & Phase

  32.1 Unknown

  32.2 Research

  32.3 Preclinical

  32.4 Clinical

  32.5 Phase-I

  32.6 Phase-I/II

  32.7 Phase-II

  32.8 Phase-II/III

  32.9 Phase-III

  32.10 Registered

 

33. Marketed Multiple Cancer Monoclonal Antibodies Clinical Insight

  33.1 Cetuximab (Erbitux)

  33.2 Nivolumab (Opdivo)

  33.3 Bevacizumab (Avastin)

  33.4 Trastuzumab (Herceptin)

  33.5 Atezolizumab (TECENTRIQ)

  33.6 Rituximab (MabThera & Rituxan)

  33.7 Ramucirumab (Cyramza, Sairamza & Silamza)

  33.8 Trastuzumab Biosimilar (Herzuma)

  33.9 Pembrolizumab (Keytruda)

  33.10 Pembrolizumab Companion Diagnostic (PD-L1 IHC 22C3 pharmDx)

  33.11 Ipilimumab (Yervoy)

  33.12 Trastuzumab Biosimilar (BIOMAb EGFR, CIMAher, Cimaher, Taixinsheng, TheraCIM, Theraloc & VECTHIX)

  33.13 Nimotuzumab (BIOMAb EGFR, CIMAher, Cimaher, Taixinsheng, TheraCIM, Theraloc & VECTHIX)

  33.14 Bevacizumab Biosimilar (KRABEVA)

  33.15 Bevacizumab Biosimilar (Mvasi)

  33.16 Trastuzumab Biosimilar (AryoTrust)

  33.17 Satumomab (OncoScint CR/OV)

 

34. Competitive Landscape

  34.1 Abbvie

  34.2 Amgen

  34.3 Bayer HealthCare

  34.4 Biogen Idec

  34.5 Eli Lilly

  34.6 Genmab

  34.7 Gilead Sciences

  34.8 GlaxoSmithKline

  34.9 Novartis

  34.10 Pfizer

  34.11 Roche

  34.12 Seattle Genetics


Figure 1-1: History of Development of Monoclonal Antibodies

Figure 1-2:  Working of Monoclonal Antibodies

Figure 2-1: Types of Monoclonal Antibodies

Figure 5-1: Global Biologics Market Classification

Figure 5-2: Global Market for Monoclonal Antibodies (US$ Billion), 2018-2024

Figure 5-3: Global - Bladder Cancer Monoclonal Antibodies Clinical Pipeline by Phase (%), 2018 till 2024

Figure 5-4: Global - Bladder Cancer Monoclonal Antibodies Clinical Pipeline by Phase (Number), 2018 till 2024

Figure 5-5: Global – Blood Cancer Monoclonal Antibodies Clinical Pipeline by Phase (%), 2018 till 2024

Figure 5-6: Global – Blood Cancer Monoclonal Antibodies Clinical Pipeline by Phase (Number), 2018 till 2024

Figure 5-7: Global – Breast Cancer Monoclonal Antibodies Clinical Pipeline by Phase (%), 2018 till 2024

Figure 5-8: Global – Breast Cancer Monoclonal Antibodies Clinical Pipeline by Phase (Number), 2018 till 2024

Figure 5-9: Global – Bone Cancer Monoclonal Antibodies Clinical Pipeline by Phase (%), 2018 till 2024

Figure 5-10: Global – Bone Cancer Monoclonal Antibodies Clinical Pipeline by Phase (Number), 2018 till 2024

Figure 5-11: Global – Brain Cancer Monoclonal Antibodies Clinical Pipeline by Phase (%), 2018 till 2024

Figure 5-12: Global – Brain Cancer Monoclonal Antibodies Clinical Pipeline by Phase (Number), 2018 till 2024

Figure 5-13: Global – Colorectal Cancer Monoclonal Antibodies Clinical Pipeline by Phase (%), 2018 till 2024

Figure 5-14: Global – Colorectal Cancer Monoclonal Antibodies Clinical Pipeline by Phase (Number), 2018 till 2024

Figure 5-15: Global – Head and Neck Cancer Monoclonal Antibodies Clinical Pipeline by Phase (%), 2018 till 2024

Figure 5-16: Global – Head and Neck Cancer Monoclonal Antibodies Clinical Pipeline by Phase (Number), 2018 till 2024

Figure 5-17: Global – Kidney Cancer Monoclonal Antibodies Clinical Pipeline by Phase (%), 2018 till 2024

Figure 5-18: Global – Kidney Cancer Monoclonal Antibodies Clinical Pipeline by Phase (Number), 2018 till 2024

Figure 5-19: Global – Skin Cancer Monoclonal Antibodies Clinical Pipeline by Phase (%), 2018 till 2024

Figure 5-20: Global – Skin Cancer Monoclonal Antibodies Clinical Pipeline by Phase (Number), 2018 till 2024

Figure 5-21: Global – Stomach Cancer Monoclonal Antibodies Clinical Pipeline by Phase (%), 2018 till 2024

Figure 5-22: Global – Stomach Cancer Monoclonal Antibodies Clinical Pipeline by Phase (Number), 2018 till 2024

Figure 5-23: Global – Lung Cancer Monoclonal Antibodies Clinical Pipeline by Phase (%), 2018 till 2024

Figure 5-24: Global – Lung Cancer Monoclonal Antibodies Clinical Pipeline by Phase (Number), 2018 till 2024

Figure 5-25: Global – Ovarian Cancer Monoclonal Antibodies Clinical Pipeline by Phase (%), 2018 till 2024

Figure 5-26: Global – Ovarian Cancer Monoclonal Antibodies Clinical Pipeline by Phase (Number), 2018 till 2024

Figure 5-27: Global – Pancreatic Cancer Monoclonal Antibodies Clinical Pipeline by Phase (%), 2018 till 2024

Figure 5-28: Global – Pancreatic Cancer Monoclonal Antibodies Clinical Pipeline by Phase (Number), 2018 till 2024

Figure 5-29: Global – Prostate Cancer Monoclonal Antibodies Clinical Pipeline by Phase (%), 2018 till 2024

Figure 5-30: Global – Prostate Cancer Monoclonal Antibodies Clinical Pipeline by Phase (Number), 2018 till 2024

Figure 5-31: Global – Multiple Cancer Monoclonal Antibodies Clinical Pipeline by Phase (Number), 2018 till 2024

Figure 5-32: Global – Multiple Cancer Monoclonal Antibodies Clinical Pipeline by Phase (%), 2018 till 2024

Figure 5-33: Global – Cancer Monoclonal Antibodies Clinical Pipeline by Phase (%), 2018 till 2024

Figure 5-34: Global – Cancer Monoclonal Antibodies Clinical Pipeline by Phase (Number), 2018 till 2024